TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05120791

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vegetable bouillon
Description: 14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: microalgae phaeodactylum
Description: 14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)
Description: 14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A combination of the vegetable bouillon, the microalgae and the beta-Glucan
Description: 14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
Study: NCT06004583

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical blood analysis
Description: Serum CRP and albumin levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical blood analysis
Description: Serum CRP and albumin levels
Study: NCT05546398

Intervention type: DRUG
Intervention: Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab
Description: No study drug was administered during this study.

Intervention type: OTHER
Intervention: No study drug
Description: No study drug was administered during this study.
Study: NCT06441162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized 3% sodium chloride solution
Description: Standardized dose of nebulized 3% sodium chloride will be provided from 4 mL vial and administered be every 6 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest percussion cups
Description: The chest percussion cup is a small, flexible cup made of vinyl that is used to provide gentle chest wall vibrations to assist with airway clearance and is utilized in patients of all ages with sputum production, such as those with acute bronchiolitis. Administered every 6 hours while on supplemental oxygen therapy.
Study: NCT05151861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete removal of pharmacological treatment
Description: Removal of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Maintenance of pharmacological treatment
Study: NCT06710782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Patients underwent intra-articular hyaluronic acid injection.
Study: NCT06401850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Group
Description: The intervention provided to the training group focuses on improving skills to cope with polycystic ovary syndrome. This intervention includes topics such as encouraging healthy lifestyle habits, raising awareness about nutrition and exercise, teaching stress management techniques, and offering strategies to support hormonal balance. It provides participants with the tools they need to understand and manage symptoms that impact their lives. It also provides a supportive environment, encouraging participants to share their experiences with each other and receive support. This intervention aims to improve individuals' overall quality of life while strengthening their ability to manage their own health and well-being.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: No intervention was made to the control group. This group did not receive additional training or support to cope with polycystic ovary syndrome. In this way, the effects of the control group on lifestyle, symptom management and overall quality of life were evaluated in comparison with the training group. This approach focuses on determining the direct effects of the intervention, while allowing to observe the natural course of the control group, and the results help to provide a clear assessment of the effectiveness of the intervention.
Study: NCT06522672

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: My Happy Flo
Description: The intervention aims to alleviate period symptoms including heavy flows, prolonged periods, cramps, mood disturbances, energy levels, cycle regulation, and fatigue. Blood tests for Vitamin D and Iron levels will be conducted at Baseline and after the third menstrual cycle. Participants will complete validated questionnaires assessing period symptoms after each menstrual cycle.
Study: NCT06256302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverses Abdominis Plane Block
Description: Transverses abdominis plane block will be provided randomly using prospective double-blinding.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local wound infiltration
Description: Local wound infiltration will be provided randomly using prospective double-blinding.
Study: NCT06477939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of L-TC
Description: Administration of L-TC (300 mg) as an IV perfusion, before each radiotion session~Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus Temozolomide
Description: Radiotherapy : delivered at 40.5 Gy in 15 fractions of 2.7 Gy - One fraction a day 5 fractions per week~+ Temozolomide delivered at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 25 days.
Study: NCT06309043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant anti-EGFR human/murine chimeric monoclonal antibody injection
Description: a single dose，250 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant anti-EGFR human/murine chimeric monoclonal antibody injection
Description: a single dose，250 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant anti-EGFR human/murine chimeric monoclonal antibody injection
Description: a single dose，250 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant anti-EGFR human/murine chimeric monoclonal antibody injection
Description: a single dose，250 mg/m2
Study: NCT06710782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous pulsed radiofrequency
Description: Patients underwent transcutaneous pulsed radiofrequency application plus genicular nerve block.
Study: NCT06709066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mivacurium chloride
Description: mivacurium chloride 0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion
Study: NCT05192512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2928 injection
Description: TQB2928 injection is a CD47 Blocker.
Study: NCT05274789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in the experimental group were given a loading dose of 0.6 μg/kg of dexmedetomidine intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients in the experimental group were given a loading dose of 0.6 μg/kg of saline intravenously after 10 minutes of intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the surgery.
Study: NCT04610684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin 5-6 mg/mL/min AUC will be delivered over 30 - 60 minutes intravenously on Day 1 of each 21 day Cycle after completion of atezolizumab. For 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 80-100 mg/m2 will be delivered over 60 minutes intravenously on Days 1-3 of each 21 day Cycle after completion of carboplatin (Day 1 only). For 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be delivered over 60 (± 15) minutes intravenously on Day 1 of each 21 day Cycle for 4 cycles then continue as monotherapy maintenance with the same schedule.
Study: NCT04773002

Intervention type: OTHER
Intervention: Different anesthesia methods
Description: Total intravenous anesthesia (TIVA)and volatile anesthesia

Intervention type: OTHER
Intervention: Different anesthesia methods
Description: Total intravenous anesthesia (TIVA)and volatile anesthesia
Study: NCT06360926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SuperSonic® Ultrasound System
Description: SuperSonic® Ultrasound System equipped with new software iterations used with a new probe and CE marked probes. The new software and probe are the new study investigational device not CE marked
Study: NCT06709066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: succinylcholine
Description: succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion)
Study: NCT06708663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX009+IN10018
Description: The 7.5 mg/kg dose group will first enroll 3 to 6 subjects, and if the 7.5 mg/kg dose group is tolerable, then 3 to 6 subjects will continue to be enrolled into the 10 mg/kg dose group; if the 7.5 mg/kg dose group is not tolerable, a decision will be made to add a new, lower dose group after discussion between the sponsor and the investigator; in addition, based on the available study data, the sponsor and the investigator will discuss and decide whether to add an unplanned dose group or an exploratory group and decide on the appropriate recommended dose (RP2D) for the Phase IIa study.~IN10018 is fixed dose at 100mg daily.
Study: NCT06710470

Intervention type: DRUG
Intervention: Deucravacitinib
Description: As per product label

Intervention type: DRUG
Intervention: Deucravacitinib
Description: As per product label

Intervention type: DRUG
Intervention: Deucravacitinib
Description: As per product label

Intervention type: DRUG
Intervention: Systemic psoriasis medications
Description: As per product label

Intervention type: DRUG
Intervention: Systemic psoriasis medications
Description: As per product label

Intervention type: DRUG
Intervention: Systemic psoriasis medications
Description: As per product label

Intervention type: OTHER
Intervention: No systemic medications
Description: Participants not exposed to any systemic medications

Intervention type: OTHER
Intervention: No systemic medications
Description: Participants not exposed to any systemic medications

Intervention type: OTHER
Intervention: No systemic medications
Description: Participants not exposed to any systemic medications
Study: NCT06708169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preemptive education provided by anesthesiologists
Description: A preemptive education about 4 stages (prepare, anethesia, surgery, and recovery) by anesthesiologists within 15 minute.
Study: NCT06707597

Intervention type: OTHER
Intervention: Patient Interaction Group
Description: No interventions or procedures will be applied to the patients. To evaluate whether the pain, anxiety, and comfort of patients undergoing the same surgical procedure are influenced by each other, the average scale scores of patients in double and single rooms will be compared.
Study: NCT06710847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4418959
Description: GSK4418959 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4418959
Description: GSK4418959 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4418959
Description: GSK4418959 will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: PD-1 inhibitor will be administered.
Study: NCT06709807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-378 25/1000mg
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-378 25/1000mg
Description: QD, PO
Study: NCT06708936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KSD-201
Description: Patients will receive approximately 5x10\^6 cells/dose DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
Study: NCT06705907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Achieving Independence and Mastery in School (AIMS)
Description: Intervention targeting academic executive functioning

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Building Essential Social Skills for Teens (BESST)
Description: Intervention targeting social skills
Study: NCT06705218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINDSET
Description: 2.5-hour mHealth intervention consisting of three modules containing brief films and corresponding interactive reflection activities aimed to improves whole patient health (physical, social, emotional, and functional quality of life as measured by the FACT-G) in patients undergoing systemic treatment for cancer with curative intent. Films feature interviews with people living with cancer describing their experience with diagnosis, treatment, and recovery, and the importance of their mindsets during their experience. The films also feature Stanford faculty with expertise in oncology, psychiatry, and psychology who offer a scientific framework for the importance of mindsets during cancer treatment and provide examples from their clinical practices. The reflection exercises that follow the films are designed to help patients craft a personalized strategy (a) for changing maladaptive mindsets and maintaining adaptive ones and (b) for translating ideas from the film into actionable behavior

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Information Series for Cancer
Description: This behavioral intervention provides educational information on coping strategies for individuals undergoing cancer treatment through a hybrid of videos and corresponding questions.
Study: NCT06708416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-1110
Description: ONO-1110 tablets once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily
Study: NCT06710223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: Toll-like receptor 9 (TLR9) agonist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryoablation of liver

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Anti-CTLA4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PDL1
Study: NCT06707363

Intervention type: PROCEDURE
Intervention: orthopedic surgery
Description: Surgeries involving major interventions on the musculoskeletal system, such as joint replacement surgeries or fracture repairs.
Study: NCT05603858

Intervention type: PROCEDURE
Intervention: Tenodesis by end button
Description: open reduction of the dislocated hip and stabilization by end button
Study: NCT05626283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transforaminal epidural injection.
Description: transforaminal epidural steroid injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: micro RNA-155 serum level
Description: Estimation of miR-155 expression level:

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: micro RNA-155 serum level
Description: Estimation of miR-155 expression level:
Study: NCT05628662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery System (SAFE-AP)
Description: Each subject will undergo a 32-hour in-hospital study, including 4 meals (60 grams of carbohydrates each, except 50 grams for breakfast), one overnight period and 2 unannounced aerobic exercise sessions. Each exercise session consists of three 15-minute sets on a cycle ergometer at 70% of maximum heart rate with 5 minutes of rest between sets.
Study: NCT06707870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical retraction exercise
Description: Neck retraction exercises are performed on patients either in sitting or standing in an upright position while pushing their chin backward and simultaneously raising their head within the pain-free range (3 seconds hold)of 10 repetitions in each session at sitting position. Conventional treatment (TENS (2 to 10 Hz),10 mints, Heating pad, stretching of tight muscles Trapezius and SCM)should be included.~The patients will received 20-30-minute sessions on 3 alternate days for two consecutive weeks, making it a total of 6 sessions. Patients were advised to revisit after 4 weeks (1 month from the baseline) for follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facet oscillatory mobilization
Description: Facet joint oscillatory mobilization on the cervical spine C2-C7(6 to 10 repetitions in each session) in the sitting position.~Conventional treatment (TENS (2 to 10 Hz) 10 mints, Heating pad, stretching of tight muscles Trapezius and SCM) should be included.~The patients will received 20-30-minute sessions on 3 alternate days for two consecutive weeks, making it a total of 6 sessions. Patients were advised to revisit after 4 weeks (1 month from the baseline) for follow-up.
Study: NCT06708052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: voodoo flossing
Description: The voodoo flossing intervention used the standard voodoo flossing, wrapping a voodoo flossing (lime green Sanctband Comprefloss™, 2 × 3.5 m; PENTEL, Shah Alam, Malaysia) made of natural rubber tightly around the ankle on the affected side. It was started at the fifth metatarsal and wrapped horizontally around the metatarsals twice, in a figure eight to the medial malleolus, over the Achilles tendon and the lateral malleolus three times, and around the medial malleolus again, before being passed twice from the medial mal-leolus over the Achilles tendon to the lateral malleolus, forming an end knot

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The control group did not use voodoo flossing.
Study: NCT06707038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic intervention
Description: AATAP is a program created to address the barriers that Black patients face when accessing transplantation. AATAP providers resources in cultural congruency, trust, psychosocial support, and health literacy to provide patients with the individualized support needed to access the kidney transplant waitlist
Study: NCT06710626

Intervention type: DEVICE
Group type: OTHER
Intervention: Assistive Robotic Arm
Description: The intervention involves using the N1 Implant, a wireless brain-computer interface (BCI), to enable participants to control the Assistive Robotic Arm through neural signals.
Study: NCT06708611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: torsemide
Description: Extended release formulation of torsemide
Study: NCT05311150

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narrow band imaging bronchoscopy guided endobronchial biopsy
Description: Examination of the airways will be performed with the narrow band imaging mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: White light bronchscopy guided endobronchial biopsy
Description: Examination of the airways will be performed with the white light bronchoscopy mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
Study: NCT06708611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: torsemide
Description: Extended release formulation of torsemide
Study: NCT06733129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: direct IV injection
Description: direct IV injection at dosage of 2 mg/kg (adjusted body weight if BMI \> 30) after completing pre-oxygenation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: direct IV injection
Description: direct IV injection at dosage of 2 mg/kg (adjusted body weight if BMI \> 30) after completing pre-oxygenation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of Ketamine and Propofol
Description: combination of Ketamine and Propofol described above: consecutive direct IV injection of Ketamine 1 mg/kg and Propofol 1 mg/kg (adjusted body weight if BMI \> 30). Dilution are not necessary.
Study: NCT06706843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transtheoretical Model Based Motivational Interviewing
Description: Transtheoretical Model Based Motivational Interviewing was applied to haemodialysis patients in 6 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine clinical care
Description: routine clinical care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine clinical care
Description: routine clinical care
Study: NCT06745349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Course
Description: The Sleep Course previously developed and evaluated in Australia will be delivered to clients meeting participation criteria. The Sleep Course is four lessons long and is offered with once weekly therapist support for 8 weeks where clients are encouraged to email the assigned therapist for support each week. The therapist reviews client progress in the Course and emails clients once per week on a designated check in date. Sometimes the therapist will call the client. Phone calls are typically made if a client is not logging in or if the therapist feels that a phone call would be a helpful way to provide support.
Study: NCT06744023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To examine the effect of the improved environment according to Watsons Human Care Theory on sleep quality, anxiety, and depression in patients undergoing open heart surgery.
Description: The patients who underwent open heart surgery and who were in the experimental group were admitted to the ward from the postoperative intensive care unit and the environment was improved for three days based on the improved environment of Watson's HCT, and on the morning of the fourth day in the clinic, the patients were interviewed face to face and the Personal Information Form, RSCQ and HAD Scale were completed. The following improvements were implemented within the scope of environmental improvement:~* Considering the seasonal conditions, the patient room was ensured to have appropriate temperature (18-26 °C) and humidity values (30-60%), and the temperature and humidity were gradually reduced and maintained in the appropriate range by monitoring at 21:00, 22:00, and 23:00 (Days 1, 2, and 3)~* In line with the environmental arrangements, the brightness of the light in the patient room was gradually reduced at 21:00, 22:00, and 23:00 using the Light Meter LM-3000 (Days 1, 2, and 3)
Study: NCT06745830

Intervention type: OTHER
Intervention: No intervention
Description: No intervention